US to receive cut of Pfizer and Lilly's overseas price increases under new pacts

Pfizer and Eli Lilly have signed agreements with the Trump administration that would direct a portion of any revenue gains from higher drug prices abroad to the US government. These "most favored nation" arrangements are intended to tie US pricing to international benchmarks and could reshape how the companies set global prices. The specifics of the revenue-sharing terms were not disclosed, but the deals signal a new approach to leveraging foreign markets for domestic benefit.

The agreements mark a notable shift in how the U.S. government seeks to influence pharmaceutical pricing, moving beyond domestic negotiation toward directly tying American drug costs to benchmarks set in other countries. By linking revenue gains from overseas price increases to federal payments, the administration aims to capture some of the profits that drugmakers earn in markets where prices are often higher than in the U.S. This approach could create new incentives for companies to moderate foreign price hikes, though the lack of disclosed terms leaves the practical impact unclear. The deals also highlight ongoing tensions between global pricing strategies and domestic affordability concerns.